National Pension Service Has $38.84 Million Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

National Pension Service cut its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.5% in the 4th quarter, Holdings Channel reports. The institutional investor owned 367,737 shares of the medical equipment provider’s stock after selling 1,810 shares during the quarter. National Pension Service’s holdings in Zimmer Biomet were worth $38,844,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of ZBH. Stonebridge Financial Group LLC acquired a new position in shares of Zimmer Biomet during the fourth quarter worth $25,000. Dunhill Financial LLC increased its holdings in shares of Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 218 shares in the last quarter. Ashton Thomas Securities LLC acquired a new position in shares of Zimmer Biomet during the third quarter worth $28,000. Brooklyn Investment Group acquired a new position in shares of Zimmer Biomet during the third quarter worth $35,000. Finally, Kentucky Trust Co acquired a new position in shares of Zimmer Biomet during the fourth quarter worth $39,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Trading Up 0.3 %

ZBH opened at $104.32 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $97.69 and a fifty-two week high of $133.90. The firm has a market capitalization of $20.77 billion, a PE ratio of 23.44, a P/E/G ratio of 1.95 and a beta of 1.02. The company’s 50-day moving average is $105.72 and its 200 day moving average is $107.38.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period last year, the firm posted $2.20 EPS. As a group, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.24 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.92%. Zimmer Biomet’s dividend payout ratio (DPR) is 21.57%.

Analysts Set New Price Targets

A number of analysts recently weighed in on ZBH shares. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. JMP Securities restated a “market outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. Barclays decreased their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday, February 10th. Royal Bank of Canada decreased their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Finally, Truist Financial restated a “hold” rating and issued a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.